Potassium

Potassium

SCHEMBL367653

Cc1ccc(S(=O)(O)=S)cc1.[K]

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.54
CA1 P00915 3/20 0.50
CA2 P00918 3/20 0.50
MMP2 P08253 2/20 0.50
MMP1 P03956 1/20 0.50
MMP9 P14780 1/20 0.50
MMP8 P22894 1/20 0.50
MMP13 P45452 1/20 0.50
CA12 O43570 1/20 0.50
CA3 P07451 1/20 0.50
CA6 P23280 1/20 0.50
CA5A P35218 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
CA5B Q9Y2D0 1/20 0.50
TLR9 Q9NR96 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.46
F2 P00734 1/20 0.45
PRSS1 P07477 1/20 0.45
PRSS2 P07478 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL338046 0.98 GAA (0.56) GAACA1CA2MMP2MMP1
SCHEMBL3818649 0.98 GAA (0.56) GAACA1CA2MMP2MMP1
Propane SCHEMBL3021103 0.91 GAA (0.50) GAACA1CA2MMP2MMP1
SCHEMBL3016245 0.87 GAA (0.46) GAACA1CA2MMP2MMP1
Thiocyanic Acid SCHEMBL8512493 0.84 GAA (0.43) GAACA1CA2MMP2MMP1
Chlorobenzene SCHEMBL3023979 0.84 ALDH1A1 (0.47) GAACA1CA2CA12CA9
Benzenethiol SCHEMBL8487581 0.82 CA12 (0.43) GAACA1CA2MMP2MMP1
SCHEMBL7949872 0.82 CYP2C19 (0.42) GAACA1CA2MMP2MMP1
Thiosulfuric Acid SCHEMBL28402065 0.81 GAA (0.54) GAACA1CA2MMP2MMP1
Potassium SCHEMBL30108988 0.80 GAA (0.59) GAACA1CA2MMP2MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3831841-A1 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF S&T Global Inc. (US) 2021-06-09 EP disclosed
US-20190151403-A1 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF S&T GLOBAL INC. 2019-05-23 US disclosed
EP-3458470-A1 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF S&T Global Inc. (US) 2019-03-27 EP disclosed
US-10077241-B2 Tetrahydro-benzoimidazolyl modulators of TGR5 JANSEN PHARMACEUTICA NV (BE) 2018-09-18 US disclosed
WO-2017200984-A1 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF S&T GLOBAL INC. (US) 2017-11-23 WO disclosed
US-20170101445-A1 NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION S&T GLOBAL INC. 2017-04-13 US disclosed
US-9573978-B2 Cyclosporin derivatives for the treatment and prevention of a viral infection S&T GLOBAL, INC. (US) 2017-02-21 US disclosed
US-20170029381-A1 TETRAHYDRO-BENZOIMIDAZOLYL MODULATORS OF TGR5 JANSSEN PHARMACEUTICA NV (BE) 2017-02-02 US disclosed
US-20160052972-A1 NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION S&T GLOBAL INC. 2016-02-25 US disclosed
US-9217015-B2 Cyclosporin derivatives for the treatment and prevention of a viral infection S&T GLOBAL INC. (US) 2015-12-22 US disclosed
US-6306863-B1 TREATMENT OF ASTHMA WITH CAMPOUNDS ASTRAZENECA AB (SE) 2001-10-23 US disclosed
US-6229013-B1 PRODUCED BY HYDROGENATION AND DEHALOGENATION IN THE PRESENCE OF A CATALYST; ANTIINFLAMMATORY AGENTS, IMMUNOSUPRESSANTS, ANTIPROLIFERATIVE AGENTS, ANTICARCINOGENIC AGENTS, AND TREATMENT OF RHEUMATIC DISEASE ASTRAZENECA UK LIMITED (GB) 2001-05-08 US disclosed
US-6211368-B1 HYDROLYSIS OF CORRESPONDING ESTER ASTRAZENECA UK LIMITED (GB) 2001-04-03 US disclosed
US-6180635-B1 NOVEL THIENO(2,3-D)PYRIMIDINEDIONES WHICH EXHIBIT PHARMACOLOGICAL ACTIVITY, IN PARTICULAR IMMUNOSUPPRESSIVE ACTIVITY; TREATING ALLOGRAFT REJECTION ASTRAZENECA UK LIMITED (GB) 2001-01-30 US disclosed
US-6166206-A Pyrrolo[3,4-D]Pyrimidinone derivatives and their use as medicaments ASTRAZENECA UK LIMITED (GB) 2000-12-26 US disclosed
US-6046204-A Pyrrolo[3,4-D] pyrimidinone derivatives and their use as medicaments ASTRA PHARMACEUTICALS LIMITED (GB) 2000-04-04 US disclosed
US-6028074-A FOR TREATING ALLOGRAFT REJECTION ASTRA PHARMACEUTICALS, LTD. (GB) 2000-02-22 US disclosed
EP-0495253-B1 Method for the photographic production of silver images AGFA GEVAERT NV (BE) 1995-05-10 EP disclosed
US-5266442-A Method for increasing the contrast of photographic silver images AGFA-GEVAERT N.V. (BE) 1993-11-30 US disclosed
EP-0495253-A1 Method for the photographic production of silver images AGFA-GEVAERT N.V. (BE) 1992-07-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052972-A1 NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION HAVCR2, TSLP, ICOS GAA 1885/4885CA1 2950/4885CA2 1240/4885
US-20190151403-A1 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF MALT1, MYLK2, FKBP1B GAA 2720/4885CA1 4153/4885CA2 1322/4885
US-10077241-B2 Tetrahydro-benzoimidazolyl modulators of TGR5 GLRA1, GRM5, TRHR GAA 3306/4885CA1 4132/4885CA2 3845/4885
US-20170029381-A1 TETRAHYDRO-BENZOIMIDAZOLYL MODULATORS OF TGR5 GLRA1, GRM5, TRHR GAA 3306/4885CA1 4132/4885CA2 3845/4885
US-20170101445-A1 NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION HAVCR2, TSLP, HLA-DRB1 GAA 1815/4885CA1 2992/4885CA2 1103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.